Conversion From Fast Acting Oral Opioids to Abstral®

PHASE4TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 21, 2011

Primary Completion Date

December 7, 2011

Study Completion Date

December 7, 2011

Conditions
Pain
Interventions
DRUG

SL fentanyl

SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.

Trial Locations (1)

SE-141 86

Smärtavdelning B42, Anestesikliniken Karolinska University Hospital, Huddinge, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Orexo AB

INDUSTRY

NCT01315886 - Conversion From Fast Acting Oral Opioids to Abstral® | Biotech Hunter | Biotech Hunter